Research Affiliates Deletions ETF
NIXT - ETF AI Analysis
Top Page
Research Affiliates Deletions ETF (NIXT)
NIXT’s rating suggests it is a solid but not top-tier ETF, with its quality driven by strong holdings like Qualys and Paycom, which benefit from robust profitability, cash flow, and strategic growth in cybersecurity and HR software. However, weaker positions such as Maravai Lifesciences and Avantor, both facing declining revenues and profitability, weigh on the fund’s overall appeal. A key risk is the fund’s exposure to several companies with financial and valuation challenges, which could add volatility and pressure future returns.
NIXT vs. SPDR S&P 500 ETF (SPY)
- AUM
- 70.10M
- Region
- North America
- Expense Ratio
- 0.29%
- Beta
- 0.98
- Issuer
- RAFI Indices
- Inception Date
- Sep 09, 2024
- Dividend Yield
- 1.18%
- Asset Class
- Equity
- Index Tracked
- Research Affiliates Deletions Index - Benchmark TR Gross
NIXT Summary
NIXT is the Research Affiliates Deletions ETF, which follows the Research Affiliates Deletions Index. It focuses on U.S. companies that were recently removed from major stock indexes, aiming to find overlooked value and long-term growth. The fund invests across many sectors, including technology, health care, and consumer companies, with well-known names like Moderna and Okta among its holdings. Someone might invest in NIXT to diversify beyond the usual big index stocks and potentially benefit from undervalued companies. A key risk is that these deleted stocks can be more volatile and may go up or down more than the broader market.
How much will it cost me?
This ETF has an expense ratio of 0.19%, which means you’ll pay about $1.90 per year for every $1,000 you invest. That’s slightly higher than the cheapest broad index ETFs, because this fund uses a more specialized, actively designed strategy focusing on stocks deleted from major indices.
What would affect this ETF?
This ETF focuses on U.S. companies that have been dropped from major indexes, so it could benefit if value investing comes back into favor, smaller and overlooked stocks recover, and sectors like technology and health care (including holdings such as Moderna and Okta) grow as innovation and consumer spending strengthen. On the downside, higher interest rates, a weak U.S. economy, or sector-specific setbacks in tech and health care could hurt these more volatile, recently deleted stocks, and changes in market rules or index construction could also reduce the pool of attractive opportunities for the fund.
NIXT Top 10 Holdings
NIXT is leaning heavily into U.S. tech and health care names, with a clear tilt toward beaten-up, recently deleted stocks that are starting to find their footing. Moderna has been rising again and is a key engine for performance, while cybersecurity players like Qualys and Tenable are quietly pulling their weight with steady to strong momentum. Insight Enterprises and RingCentral add to the tech-heavy flavor, contributing mixed but generally positive trends. On the flip side, Maravai Lifesciences and Avantor are still lagging, acting as small anchors on an otherwise improving, contrarian portfolio.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MRNA | Moderna | 2.28% | $1.61M | $100.63B | 766.15% | 59Neutral |
 OKTA | Okta | 1.03% | $727.00K | $31.86B | 115.54% | 75Outperform |
 NSIT | Insight Enterprises | 0.98% | $693.86K | $4.88B | 88.60% | 62Neutral |
 MRVI | Maravai Lifesciences Holdings | 0.88% | $622.18K | $2.00B | 136.31% | 49Neutral |
 CRL | Charles River Labs | 0.87% | $609.99K | $16.42B | 98.72% | 60Neutral |
 TENB | Tenable Holdings | 0.87% | $615.70K | $4.49B | 49.22% | 61Neutral |
 QLYS | Qualys | 0.88% | $620.42K | $6.38B | 15.35% | 78Outperform |
 SWKS | Skyworks Solutions | 0.89% | $625.66K | $20.58B | 29.61% | 70Outperform |
 AVTR | Avantor | 0.82% | $579.93K | $10.66B | 35.24% | 48Neutral |
 SGRY | Surgery Partners | 0.80% | $563.49K | $3.49B | 67.59% | 53Neutral |
NIXT Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NIXT, the sentiment is Positive. The current price of 35.60 is above the 20-day moving average (MA) of 35.30, above the 50-day MA of 34.09, and above the 200-day MA of 31.47, indicating a bullish trend. The MACD of 0.56 indicates Positive momentum. The RSI at 55.28 is Neutral, neither overbought nor oversold. The STOCH value of 49.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NIXT.
NIXT Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| NIXT | $35.60 | $38.00(6.75% Upside) | $70.10M | 0.29% | 63Neutral |
 CVSM | $26.47 | $29.40(11.06% Upside) | $96.01M | 0.55% | 61Neutral |
 POMG | $27.32 | $33.75(23.54% Upside) | $79.20M | 0.68% | 66Neutral |
 FSCS | $37.78 | $42.27(11.87% Upside) | $62.80M | 0.60% | 74Outperform |
 DEEP | $42.25 | $49.61(17.40% Upside) | $25.47M | 0.80% | 67Neutral |
 EPSV | $29.44 | $35.15(19.38% Upside) | $5.91M | 0.88% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NIXT | Research Affiliates Deletions ETF | 35.60 | 10.90 | 44.11% | |
| CVSM | CresAlta Small and Mid-Cap ETF | 26.47 | 1.38 | 5.51% | |
| POMG | PRIMECAP Odyssey Discovery ETF | 27.32 | 1.80 | 7.05% | |
| FSCS | First Trust Smid Capital Strength Etf | 37.78 | 2.96 | 8.49% | |
| DEEP | Roundhill Acquirers Deep Value ETF | 42.25 | 8.77 | 26.18% | |
| EPSV | Harbor SMID Cap Value ETF | 29.44 | 6.48 | 28.22% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.